MOREPENLAB Stock Overview
Morepen Laboratories Limited desarrolla, fabrica, comercializa y vende principios activos farmacéuticos (API), formulaciones y productos de salud a domicilio en India, Estados Unidos y a escala internacional.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for MOREPENLAB from our risk checks.
Morepen Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹47.70 |
| 52 Week High | ₹56.40 |
| 52 Week Low | ₹25.10 |
| Beta | 1.25 |
| 1 Month Change | 2.36% |
| 3 Month Change | -6.01% |
| 1 Year Change | 77.99% |
| 3 Year Change | 33.24% |
| 5 Year Change | 166.48% |
| Change since IPO | -69.08% |
Recent News & Updates
Recent updates
Morepen Laboratories (NSE:MOREPENLAB) Seems To Use Debt Quite Sensibly
Nov 23
Increases to CEO Compensation Might Be Put On Hold For Now at Morepen Laboratories Limited (NSE:MOREPENLAB)
Sep 22Is Morepen Laboratories (NSE:MOREPENLAB) Using Too Much Debt?
Aug 10Increases to CEO Compensation Might Be Put On Hold For Now at Morepen Laboratories Limited (NSE:MOREPENLAB)
Sep 21Should You Be Adding Morepen Laboratories (NSE:MOREPENLAB) To Your Watchlist Today?
Apr 05Do Morepen Laboratories's (NSE:MOREPENLAB) Earnings Warrant Your Attention?
Sep 14Is Morepen Laboratories (NSE:MOREPENLAB) Using Too Much Debt?
May 21Does Morepen Laboratories (NSE:MOREPENLAB) Deserve A Spot On Your Watchlist?
Mar 12Our View On Morepen Laboratories' (NSE:MOREPENLAB) CEO Pay
Feb 22Is Morepen Laboratories Limited's (NSE:MOREPENLAB) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Feb 07Morepen Laboratories (NSE:MOREPENLAB) Shareholders Have Enjoyed A 91% Share Price Gain
Jan 21Morepen Laboratories (NSE:MOREPENLAB) Has A Pretty Healthy Balance Sheet
Jan 03
Is There More To The Story Than Morepen Laboratories's (NSE:MOREPENLAB) Earnings Growth?
Dec 16Should You Be Adding Morepen Laboratories (NSE:MOREPENLAB) To Your Watchlist Today?
Nov 28Could The Morepen Laboratories Limited (NSE:MOREPENLAB) Ownership Structure Tell Us Something Useful?
Nov 09Can You Imagine How Morepen Laboratories' (NSE:MOREPENLAB) Shareholders Feel About The 75% Share Price Increase?
Oct 13Morepen Laboratories Limited's (NSE:MOREPENLAB) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Sep 17Morepen Laboratories Limited's (NSE:MOREPENLAB) Earnings Haven't Escaped The Attention Of Investors
Aug 26Is Now The Time To Put Morepen Laboratories (NSE:MOREPENLAB) On Your Watchlist?
Aug 19We Think Morepen Laboratories (NSE:MOREPENLAB) Can Stay On Top Of Its Debt
Jul 29Update: Morepen Laboratories (NSE:MOREPENLAB) Stock Gained 80% In The Last Five Years
Jul 08Shareholder Returns
| MOREPENLAB | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 5.0% | 0.006% | 1.9% |
| 1Y | 78.0% | 62.1% | 49.0% |
Rentabilidad frente al sector: MOREPENLAB superó al sector Indian Pharmaceuticals , que obtuvo un rendimiento del 64.6% el año pasado.
Rentabilidad vs. Mercado: MOREPENLAB superó al mercado Indian, que obtuvo un rendimiento del 44.7% el año pasado.
Price Volatility
| MOREPENLAB volatility | |
|---|---|
| MOREPENLAB Average Weekly Movement | 7.6% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in IN Market | 10.2% |
| 10% least volatile stocks in IN Market | 4.2% |
Precio estable de las acciones: MOREPENLAB no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de MOREPENLAB (8%) se ha mantenido estable durante el año pasado.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 1,649 | Sushil Suri | https://www.morepen.com |
Morepen Laboratories Limited desarrolla, fabrica, comercializa y vende principios activos farmacéuticos (API), formulaciones y productos de salud a domicilio en India, Estados Unidos y a escala internacional. La empresa ofrece API para medicamentos antihistamínicos, antiasmáticos, antilipémicos, antihipertensivos, antidiabéticos, anticoagulantes, antigota, antidepresivos y antipalúdicos; y productos de diagnóstico a domicilio, como purificadores de aire, esfigmomanómetros, tiras reactivas de glucosa en sangre, tensiómetros, vaporizadores sin respiración, estetoscopios, termómetros digitales, glucómetros, nebulizadores, cinturones térmicos y pulsioxímetros. También ofrece fever X para la fiebre; Pain X para el dolor; Fiber-X, un isabgol satírico; Acidity X para la acidez; Burnol, crema para quemaduras de primer grado/menores; y formulaciones para nutrición y probióticos, gastroenterología, antibióticos, ginecología, antialérgicos y sistema nervioso central, así como cardiología, diabetología y nutracéuticos.
Morepen Laboratories Limited Fundamentals Summary
| MOREPENLAB fundamental statistics | |
|---|---|
| Market cap | ₹24.37b |
| Earnings (TTM) | ₹761.20m |
| Revenue (TTM) | ₹16.42b |
32.0x
P/E Ratio1.5x
P/S RatioIs MOREPENLAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MOREPENLAB income statement (TTM) | |
|---|---|
| Revenue | ₹16.42b |
| Cost of Revenue | ₹10.73b |
| Gross Profit | ₹5.69b |
| Other Expenses | ₹4.93b |
| Earnings | ₹761.20m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.49 |
| Gross Margin | 34.65% |
| Net Profit Margin | 4.64% |
| Debt/Equity Ratio | 3.5% |
How did MOREPENLAB perform over the long term?
See historical performance and comparison